Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

35.80 +0.21 (+0.60%)
Streaming Delayed Price Updated: 9:30 AM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,795
Open 35.99
Bid (Size) 35.71 (3)
Ask (Size) 36.13 (1)
Prev. Close 35.59
Today's Range 35.80 - 35.99
52wk Range 20.14 - 40.02
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
Via Benzinga
Why EXELIXIS INC (NASDAQ:EXEL) is Poised for High Growth.
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL). 
Via Chartmill

Performance

YTD
+5.5%
+5.5%
1 Month
-5.1%
-5.1%
3 Month
-1.7%
-1.7%
6 Month
+24.9%
+24.9%
1 Year
+56.6%
+56.6%

More News

Read More
EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock and is consolidating.
Via Chartmill
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
Via Chartmill
Peering Into Exelixis's Recent Short Interest
Via Benzinga
The Smartest Biotech Stocks to Buy With $50
Via The Motley Fool
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Via Benzinga
Exposures Product Safety
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
From Exelixis, Inc.
Via Business Wire
Looking Into Exelixis's Recent Short Interest
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
What 25 Analyst Ratings Have To Say About Exelixis
Via Benzinga
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Is This The Beginning? Insights On Bearish Distribution Patterns
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Why Exelixis Stock Trounced the Market on Thursday
Via The Motley Fool
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Via Benzinga
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
From Exelixis, Inc.
Via Business Wire
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
Via Stocktwits
Bullish Setups
Via Talk Markets
Topics Stocks / Equities
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
From Exelixis, Inc.
Via Business Wire

Frequently Asked Questions

Is Exelixis, Inc. - Common Stock publicly traded?
Yes, Exelixis, Inc. - Common Stock is publicly traded.
What exchange does Exelixis, Inc. - Common Stock trade on?
Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exelixis, Inc. - Common Stock?
The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 35.80
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 04/22/25 09:30 AM ET
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 11.28B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.